Risedronate Sodium Tablet, Film Coated
Product Images NDC 65862-519
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 65862-519). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Package Label-principal Display Panel (30 mg Blister Carton (10 x 10 Unit Dose))
This is information about a medication called Risedronate Sodium Tablets. The National Drug Code (NDC) for this medication is 65862-518-78. It is a prescription medicine. The medication guide for patients is included and should be given to each patient who receives the medicine. The tablets are manufactured by Aurobindo and come in unit dose blister packs of 10 tablets each. The rest of the text is not readable and may contain errors due to (Optical Character Recognition).*
Package Label-principal Display Panel (35 mg Blister Card)
Package Label-principal Display Panel (35 mg Blister Carton)
This text appears to be a set of instructions for taking risedronate sodium tablets. They advise taking the tablet once a week on the same day, in the morning with plain water, and not eating or drinking for thirty minutes afterward. They also instruct readers to store the tablets properly, keep them out of reach of children, and read the accompanying Medication Guide. The packaging is child-resistant and contains four tablets. The tablets contain risedronate sodium hemi-pentahydrate and have a usual adult dosage, which is not provided in the text.*
Figure 2 (Risedronate Fig2)
This appears to be a table with some headings and values, likely related to a study or research on bone mineral density and changes as measured by the mean percentage change (+ SE) in lumbar spine, femoral neck and femoral trochanter. However, without additional context, it is difficult to provide a more detailed description or analysis.*
Figure 3 (Risedronate Fig3)
The text is a table with headings related to a clinical trial, including the names of drugs tested (Placebo and Risedronate Sodium 5 mg), the number of participants (n=56 for each group), and three measurements taken (Lumbar Spine, Femoral Neck, and Femoral Trochanter). No further information is available.*
Figure 4 (Risedronate Fig4)
Figure 5 (Risedronate Fig5)
Figure 6 (Risedronate Fig6)
Package Label-principal Display Panel (5 mg (30 Tablet Bottle))
This is a label for medication called Risedronate Sodium, with the drug code DG 65862-517-30. The medication comes in a bottle with 30 tablets. The label includes distribution information and dosage instructions, as well as precautions to store the medication between 20-25°C and away from children. There is also a warning not to take the medication without the prescription of a doctor.*
Package Label-principal Display Panel (5 mg Blister Carton (10 x 10 Unit-dose))
Package Label-principal Display Panel (30 mg (30 Tablet Bottle))
This is a description of the medication Risedronate Sodium, which comes in tablets form and is available only with a prescription. Each film-coated tablet contains Risdronatesodium hem-pentahydrate USP equivalent to Risedronate sodium of 30 mg. It is distributed by Aurobindo Pharma USA, and the usual adult dosage can be found in the package insert. The medication should be stored at a temperature between 25°C to 120°C. The text also includes some printing codes but no useful information.*
Chemical Structure (Risedronate Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.